Added to YB: 2024-10-31
Pitch date: 2024-10-29
MRK [bullish]
Merck & Co., Inc.
+23.07%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
Market Cap
$298.8B
Pitch Price
$98.19
Price Target
125.00 (+3%)
Dividend
2.81%
EV/EBITDA
11.34
P/E
16.60
EV/Sales
5.15
Sector
Pharmaceuticals
Category
value
Merck & Co., Inc. - $MRK
MRK: $125 PT. Keytruda/Gardasil patent cliff in 2028 (50% of rev). Pipeline: Winrevair (PAH, $8B peak), Restoret (eye diseases, $15B TAM), TROP2 & HER3 cancer drugs ($20B by 2035). Undervalued at 3% div, 10%+ rev growth, cheap P/FCF & P/E. Caution: pre-election volatility, potential 5% 10Y yield impact.
Read full article (4 min)